What is ExoAtlet?
ExoAtlet operates at the intersection of advanced robotics and clinical rehabilitation, specializing in the development of wearable exoskeletons designed for patients with spinal cord injuries, multiple sclerosis, and cerebral palsy. By integrating sophisticated mechanical engineering with evidence-based therapeutic protocols, the company provides clinicians with tools like the ExoAtlet II and ExoRehabilitation systems. These platforms are engineered to facilitate gait restoration, effectively bridging the gap between traditional physical therapy and high-tech assistive mobility. Through its global distribution network, ExoAtlet serves a diverse array of healthcare facilities, empowering medical professionals to deliver superior outcomes in patient recovery and long-term mobility management.
How much funding has ExoAtlet raised?
ExoAtlet has raised a total of $2M across 1 funding round:
Unspecified
$2M
Unspecified (2017): $2M, investors not publicly disclosed
Key Investors in ExoAtlet
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for ExoAtlet?
With this major enterprise-level funding, ExoAtlet is poised to scale its operational footprint and deepen its research and development capabilities. The strategic allocation of this capital will likely focus on expanding the clinical application of its exoskeleton technology, potentially targeting new indications for traumatic brain injury and post-arthroplasty recovery. As the company transitions into a more mature phase of its lifecycle, the focus will shift toward optimizing manufacturing efficiencies and broadening its international market presence. By continuing to refine its hardware and software integration, ExoAtlet aims to solidify its position as a leader in the assistive robotics market, ultimately driving the next generation of patient-centric rehabilitation solutions.
See full ExoAtlet company page
